



(51) International Patent Classification:

A61K 31/4748 (2006.01) *A61K 31/49* (2006.01)
A61K 31/4709 (2006.01) *A61P 25/00* (2006.01)
A61K 31/485 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/US2015/049934

(22) International Filing Date:

14 September 2015 (14.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/050,170	14 September 2014 (14.09.2014)	US
62/061,451	8 October 2014 (08.10.2014)	US
62/063,122	13 October 2014 (13.10.2014)	US
62/063,861	14 October 2014 (14.10.2014)	US
62/068,742	26 October 2014 (26.10.2014)	US
62/111,053	2 February 2015 (02.02.2015)	US
62/111,590	3 February 2015 (03.02.2015)	US
62/128,446	4 March 2015 (04.03.2015)	US
62/162,140	15 May 2015 (15.05.2015)	US
62/165,535	22 May 2015 (22.05.2015)	US
62/169,997	2 June 2015 (02.06.2015)	US
62/180,026	15 June 2015 (15.06.2015)	US
62/193,347	16 July 2015 (16.07.2015)	US
62/205,061	14 August 2015 (14.08.2015)	US
62/216,636	10 September 2015 (10.09.2015)	US
62/217,470	11 September 2015 (11.09.2015)	US
62/217,142	11 September 2015 (11.09.2015)	US

(71) Applicant: **AVANIR PHARMACEUTICALS, INC.**
 [US/US]; 30 Enterprise, Suite 400, Aliso Viejo, CA 92656
 (US).

(72) Inventor: **SIFFERT, Joao**; c/o Avanir Pharmaceuticals,
 Inc., 30 Enterprise, Suite 400, Aliso Viejo, CA 92656
 (US).

(74) Agents: **VAN HORN, Charles, E.** et al.; Finnegan,
 Henderson, Farabow, Garrett & Dunner, LLP, 901
 Newyork Avenue, N.W., Washington, DC 20001-4413
 (US).

(81) Designated States (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
 kind of regional protection available*): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA

(57) Abstract: The present disclosure is related to methods of treating agitation and/or aggression and/or associated symptoms in subjects with dementia, including, dementia associated with Alzheimer's disease. The method includes administering to a subject in need thereof a dextromethorphan compound, or a pharmaceutically acceptable salt thereof, in combination with quinidine, or a pharmaceutically acceptable salt thereof. The disclosure in certain aspects is also related to compositions that are used for treating agitation and/or aggression and/or associated symptoms in subjects suffering from Alzheimer's disease.

